FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

SPOTLIGHT: FDA committee to review ADHD risks

Tools


An FDA committee is scheduled to meet in a week to review how the agency should best study the cardiovascular risks posed by ADHD drugs. Concerns were heightened by Canada's decision to pull Adderall XR from the market last year. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about FDA   pharmaceuticals   Canada   Adderall   cardiovascular risks   ADHD